Gyre Therapeutics, Inc. (GYRE) ownership: Insider activity, 90 days: Routine (9 sales, 0 open-market buys). SEC EDGAR first-party data.
| Holder | Shares | Market Value | % Outstanding | Reported |
|---|---|---|---|---|
| Vanguard | 1201683.00 | $8.38M | not in filing | 2026-03-31 |
| BlackRock | 758630.00 | $5.29M | not in filing | 2026-03-31 |
| Geode Capital Management | 431414.00 | $3.01M | not in filing | 2026-03-31 |
| State Street | 216326.00 | $1.51M | not in filing | 2026-03-31 |
| SBI Securities Co., Ltd. | 170837.00 | $1.19M | not in filing | 2026-03-31 |
| Charles Schwab | 165238.00 | $1.15M | not in filing | 2026-03-31 |
| Northern Trust | 133841.00 | $932872.00 | not in filing | 2026-03-31 |
| Goldman Sachs | 73122.00 | $509660.00 | not in filing | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-06-11 | |
| Sell | null | 2026-06-11 | |
| Sell | null | 2026-06-11 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 | |
| Sell | null | 2026-06-10 |
Back to GYRE overview · GYRE earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.